RG6125, an anti-cadherin-11 monoclonal antibody was well-tolerated with only mild to moderate adverse events. However, RG6125 in combination with TNF inhibitor (TNFi) therapy did not show a discernible treatment effect in rheumatoid arthritis (RA) patients compared with placebo.
The protein cadherin-11, found on stromal cells in the joint, has been identified as a new target for RA treatment. Cadherin-11 is expressed on fibroblasts in joints of RA patients and increases local fibroblast-mediated inflammation, pannus formation, and tissue invasion. RG6125 is a new human monoclonal antibody directed against cadherin-11, and is believed to disrupt immune cell adhesion in a non-immunosuppressive manner.
Junker et al. aimed to assess the safety, tolerability, and efficacy of RG6125 as adjunctive treatment in patients with moderately to severely active RA and unresponsive to TNFi treatment. In this phase 2, multicentre, randomised, double-blind placebo-co...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Integrated 10-year Analysis Confirms Safety Profile Abatacept Next Article
Efficacy and Safety of E6011 in RA Patients with Inadequate Response to Methotrexate »
Table of Contents: EULAR 2019
Osteoarthritis and Osteoporosis
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.